US 12,466,808 B2
Aminopyridine derivatives and their use as selective ALK-2 inhibitors
Luca Arista, Riehen (CH); Sreehari Babu, Hyderabad (IN); Jianwei Bian, Jiangsu Province (CN); Kai Cui, Jiangsu Province (CN); Michael Patrick Dillon, Castro Valley, CA (US); Rene Lattmann, Oberwil (CH); Jialiang Li, Jiangsu Province (CN); Lv Liao, Shanghai (CN); Dimitrios Lizos, Basel (CH); Rita Ramos, Allschwil (CH); Nikolaus Johannes Stiefl, Lörrach (DE); Thomas Ullrich, Bottmingen (CH); Peggy Usselmann, Wahlbach (FR); Xiaoyang Wang, Shanghai (CN); Liladhar Murlidhar Waykole, Succasunna, PA (US); Sven Weiler, Lörrach (DE); Yubo Zhang, Shanghai (CN); Yizong Zhou, Shanghai (CN); and Tingying Zhu, Shanghai (CN)
Assigned to NOVARTIS AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Feb. 8, 2021, as Appl. No. 17/170,690.
Application 17/170,690 is a continuation of application No. 16/884,666, filed on May 27, 2020, granted, now 10,947,218.
Application 16/884,666 is a continuation of application No. 16/318,250, granted, now 10,710,980, issued on Jul. 14, 2020, previously published as PCT/CN2017/093385, filed on Jul. 18, 2017.
Claims priority of provisional application 62/364,620, filed on Jul. 20, 2016.
Prior Publication US 2021/0155606 A1, May 27, 2021
Int. Cl. C07D 401/14 (2006.01); A61P 19/00 (2006.01); A61P 19/08 (2006.01); C07D 213/82 (2006.01); C07D 401/10 (2006.01); C07D 401/12 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 411/14 (2006.01); C07D 413/00 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/00 (2006.01); C07D 419/00 (2006.01); C07D 491/107 (2006.01); C07D 491/20 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 19/00 (2018.01); A61P 19/08 (2018.01); C07D 213/82 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 411/14 (2013.01); C07D 413/00 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/00 (2013.01); C07D 419/00 (2013.01); C07D 491/107 (2013.01); C07D 491/20 (2013.01)] 13 Claims
 
1. A compound which is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide fumarate or a hydrate thereof; wherein the compound is characterized by an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 14.2, 15.6, and 18.0.